Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules by Körner, A et al.
Enzastaurin inhibits invasion and metastasis in lung cancer by
diverse molecules
AK o ¨rner
1,3, G Mudduluru
1,3, C Manegold
2 and H Allgayer*,1
1Department of Experimental Surgery Mannheim/Molecular Oncology of Solid Tumors (German Cancer Research Center-DKFZ-Heidelberg), Mannheim
Medical Faculty, Ruprecht-Karls-University Heidelberg, Mannheim 68167, Germany;
2Interdisciplinary Thoracic Oncology, Department of Surgery, Medical
Faculty Mannheim, University Heidelberg, Mannheim 68167, Germany
BACKGROUND: Enzastaurin (Enz) is a serine/threonine kinase inhibitor blocking protein kinase C (PKC)b/AKT pathway. However, an
ability of this compound to inhibit cancer invasion and metastasis is not yet clearly elucidated.
METHODS: The ability of Enz to inhibit invasion and metastasis, and to target molecules was investigated in non-small cell lung cancer
(NSCLC) by RT–PCR validated microarray, Matrigel, and in vivo chorionallantoic membrane (CAM) assays.
RESULTS: Enzastaurin significantly reduced migration, invasion, and in vivo metastasis to lungs and liver (CAM assay) of diverse NSCLC
cell lines. Genes promoting cancer progression (u-PAR, VEGFC, and HIF1a) and tumour suppression (VHL, RASSF1, and FHIT)o f
NSCLC were significantly (Po0.05) down- or upregulated after Enz treatment in H460, A549, and H1299 cells, respectively.
Luciferase/chromatin immunoprecipitation analysis showed that Enz transcriptionally controls urokinase-type plasminogen activator
receptor (u-PAR) expression by promoter inhibition through Sp1, Sp3, and c-Jun(AP-1). Moreover, siRNA knockdown of u-PAR
re-sensitised Enz-resistant cells and induced apoptosis, suggesting u-PAR as a marker of Enz resistance.
CONCLUSION: This study shows that Enz inhibits migration, invasion, and in vivo metastasis by targeting u-PAR, besides further targeting
progression-related and tumour-suppressor genes in NSCLC. Together with u-PAR being a novel putative marker of Enz response,
these data encourage molecularly tailored clinical studies on Enz in NSCLC therapy.
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Non-small cell lung cancer (NSCLC) accounts for B85% of lung
cancer cases and is the leading cause of tumour-related death
(Jemal et al, 2005; Gridelli et al, 2007), progressive stages and
metastasis being the most frequent cause for the high NSCLC
lethality. Protein kinase C (PKC) isoforms have been shown to be
highly expressed in NSCLC as compared to lung epithelial cells
(Clark et al, 2003). Activation of these isoforms contributes to
patient survival, proliferation, and the malignant progression of
human cancers including breast carcinoma (Ali et al, 2009), B-cell
lymphoma (Shipp et al, 2002), glioblastoma (da Rocha et al, 2002),
and colorectal carcinoma (Gokmen-Polar et al, 2001). Protein
kinase C signalling, which functions through serine/threonine
kinase activity, is involved in tumour-induced angiogenesis,
tumour growth, differentiation, cytokine secretion, migration,
and apoptosis, and is a prominent target for anticancer therapy
(Carducci et al, 2006). Protein kinase C activation can trigger ERK
and PI3K/AKT pathways, promoting cell proliferation and
apoptosis (Balendran et al, 2000; Goekjian and Jirousek, 2001).
Moreover, both PKC and AKT phosphorylate glycogen synthase
kinaseb (GSK3b) at Ser9, supporting the notion that these
signalling pathways overlap (Fang et al, 2002).
Enzastaurin (Enz), an acyclic bisindolylmaleimide, was initially
developed as a specific inhibitor of PKCb (Faul et al, 2003). In
addition to this major target, Enz also inhibits other PKC isoforms (d,
a, e,a n dg)( G r a f fet al, 2005). Enzastaurin was initially developed for
anti-angiogenic cancer therapy (Keyes et al, 2002), and recent
preclinical studies have shown that Enz exerts proapoptotic, growth
inhibitory, and anti-angiogenic properties in a variety of human
cancers (Keyes et al, 2002; Graff et al, 2005; Querfeld et al, 2006;
Willey et al, 2009). Moreover, in clinical studies, Enz was well
tolerated and has shown encouraging activity in a variety of tumours
(Carducci et al, 2006; Watkins et al, 2006; Hanauske et al, 2009).
Enzastaurin was shown to target the PI3K/AKT pathway, to inhibit
GSK3b and ribosomal protein S6 phosphorylation, to decrease the
expression of VEGF (Keyes et al, 2002; Graff et al, 2005) and also to
show a synergism with SUI174 and pemetrexed (Tekle et al, 2008;
Faoro et al, 2009; Giovannetti et al, 2010).
Tumour progression is a multistep process including uncon-
trolled growth, invasion, and metastasis (Douglas and Robert,
2000), which, to a considerable part, is mediated through an
abnormal regulation and function of genes. Several studies have
analysed the involvement of individual genes (Mu ¨ller-Tidow et al,
2001; Marchetti et al, 2002; Werle et al, 2004), gene expression
differences between cell lines (Chen et al, 2001; Gemma et al,
2001), and gene expression differences between primary tumours
and normal lung tissues in this context (Bhattacharjee et al, 2001;
Hellmann et al, 2001; Beer et al, 2002; Heighway et al, 2002;
Wikman et al, 2002; Zochbauer-Muller et al, 2002; Borczuk et al,
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s2003; Diederichs et al, 2004; Hayes et al, 2006). The urokinase-type
plasminogen activator (u-PA) and its receptor (u-PAR) are
essential for proteolysis in many solid tumours, the main
mechanism being the activation of plasminogen-dependent
proteolysis and a cascade of protolytic activities, leading to
extracellular matrix degradation, invasion, intravasation, and
metastasis establishment (Jo et al, 2003; Dass et al, 2008).
Extensive clinical studies have shown that the expression of
u-PAR, u-PA, and its specific inhibitor PAI-1 is associated with
tumour recurrence and poor survival of diverse cancer types
(Werle et al, 2004; Beyer et al, 2006). In addition to the u-PAR, an
overexpression of further molecules such as hypoxia-inducible
factor 1a (HIF1a), a transcription factor, and vascular endothelial
growth factor C (VEGFC), a major inducer of angiogenesis, has
been specifically shown to correlate with poor prognosis, tumour
progression, and metastasis of NSCLC (Zhang et al, 2007; Wang
et al, 2009). Genes u-PAR, HIF1a, and VEGFC are transcriptionally
activated by, for example, MAPK- and/or PI3K/AKT-related
pathways (Jo et al, 2003; Tsai et al, 2003; Phillips et al, 2005;
Skurk et al, 2005). Tumour-suppressor genes VHL, RASSF1, and
FHIT are downregulated in NSCLC (Zochbauer-Muller et al, 2002;
Hayes et al, 2006), which are implicated in the ubiquitin ligase
system (Karhausen et al, 2005), cell-cycle regulation (Dammann
et al, 2000), and apoptosis (Ji et al, 1999), respectively.
Although Enz has been reported to reduce tumour growth and to
enhance apoptosis, a potential ability of this compound to inhibit
invasion and metastasis as the most important characteristics of
malignant tumours has never been studied. Therefore, this study
was conducted to (1) determine the effects of Enz on migration,
invasion, and in vivo metastasis; and (2) determine and implicate
first molecular targets mediating this ability of Enz in NSCLC.
Furthermore, in a systematic profiling approach we sought to give
general insights into important target molecules of Enz in NSCLC.
Our study reveals that PKC inhibition by Enz reduces NSCLC
proliferation, migration, invasion, and in vivo metastasis. Moreover,
we show that u-PAR, VEGFC,a n dHIF1a, among other targets, are
being downregulated, and the tumour-suppressor genes FHIT,
RASSF1,a n dVHL are upregulated upon Enz treatment. We further
describe u-PAR as an essential target being transcriptionally
regulated by Enz through Sp1, Sp3, and c-Jun(AP-1) binding to
the promoter, and as a putative novel marker of Enz sensitivity.
MATERIALS AND METHODS
Materials, cell lines, and reagents
Enzastaurin (in DMSO) was a generous gift from Eli Lilly
(Indianapolis, IN, USA). All cell lines (H460, LXF289, A427, H1395,
A549, and H1299) were obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA) and cultured in ATCC-
recommended medium (10% FBS, 371C, 5% CO2). Fertilised special
pathogen-free eggs were from Charles River (Hilden, Germany).
Antibodies used for supershift/chromatin immunoprecipitation
analysis (ChIP) experiments were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA): p-c-Jun (sc-822x), JunD (sc-74x), JunB (sc-
46x), c-Fos (sc-52x), FosB (sc-7203x), Fra-1 (sc-22794x), Fra-2 (sc-
604x), Sp1 (sc-59x), Sp3 (sc-644x), and unspecific IgG (sc-2338).
Western blot antibodies against phospho-PKC(PAN) 9371, phospho-
p44/42(Thr202/Tyr204) 4370, p44/42 9102, phospho-GSK3b(Ser9)
9336, and phospho-Akt(Ser473) 4058 were from Cell Signaling,
Danvers, MA, USA, and Akt1 (sc-1618) and b-Actin (sc-1616R) were
from Santa Cruz Biotechnology.
Proliferation assay
Cells (3 10
3) per well were seeded in a 96-well plate in a total
volume of 100ml medium with 10% FBS. After 24h, cells were
treated either with DMSO or Enz at concentrations between 0 and
15mM. After 72h, the growth inhibitory effect was evaluated using
20ml per well of CellTiter96 AqueousOneSolution (Promega,
Madison, WI, USA) according to the manufacturer’s instructions.
Wound-healing assay
Cells (3 10
5) per well were seeded in a 24-well plate in a total
volume of 500ml medium (10% FBS). After 24h, the medium was
changed to serum-free and a wound created in the monolayer by
using a pipette tip. Cells were washed twice (PBS), and incubated
with fresh medium supplemented with DMSO or Enz. In case of
EGF stimulation, EGF (100nM) was added 4h after initial DMSO or
Enz treatment. Digital pictures were taken at 0 and 48h. To
quantify migration, we calculated the diameter of the wound as the
average of three different locations.
Matrigel invasion assay
Cells (1 10
5), starved in serum-free medium (24h), were plated
on transwell chambers precoated with 10mg Matrigel. DMSO or
Enz was applied to bottom and top chambers. In case of EGF, cells
were pretreated (4h) with DMSO or Enz, followed by EGF
(100nM). 10% FBS medium in the bottom chamber was used as
a chemoattractant. After 24h, noninvading cells were removed
with cotton swabs. Invaded cells were trypsinised and counted
using the ATP luminescence-based motility-invasion assay as
described (Leupold et al, 2007).
cDNA labelling, array hybridisation, and data analysis
Total RNA was isolated as described (Mudduluru and Allgayer,
2008), and probe labelling and array hybridisation on Illumina
Human Sentrix-8 BeadChip arrays (Illumina, San Diego, CA, USA)
were conducted according to Illumina’s recommended sample
labelling procedure based on the modified Eberwine protocol
(Eberwine et al, 1992). Scanning was carried out using a Beadstation
a r r a ys c a n n e r ,a d j u s t e dt oas c a l i n gf a c t o ro f1a n dP M Ts e t t i n g sa t
430. Data extraction was carried out for all beads individually, and
outliers were removed when median absolute deviation was 42.5.
All remaining data points were used for the calculation of the mean
average signal for a given probe, and standard deviation for each
probe was calculated. Data analysis was carried out by normalisation
of the signals using the quantile normalisation algorithm without
background subtraction, and differentially regulated genes defined
by calculating the standard deviation differences of a given probe in
a one-by-one comparison of samples.
Luciferase reporter assay
Cells were transiently transfected with 500ng of  398/þ51 u-PAR
WT/Sp1- or AP1-mutant plasmid, or with pGL3 basic (Allgayer
et al, 1999), and 50ng of Renilla-luciferase plasmid as a
transfection control using Effectene (Qiagen, Hilden, Germany).
After 24h, cells were treated with DMSO or Enz for another 24h,
and reporter assays performed using the Dual-Luciferase reporter
assay system (Promega).
Real-time PCR
Total RNA isolation and cDNA synthesis was performed as
described (Mudduluru and Allgayer, 2008). The u-PAR
(Hs00182181; Applied Biosystems, Carlsbad, CA, USA) mRNA
was quantified using TaqMan Universal PCR Master Mix and b-
Actin (Human ACTB 4333762F; Applied Biosystems) as house-
keeping gene. Quantification of HIF-1a, VEGFC, VHL, RASSF1,
FHIT, Sp1, Sp3, and c-Jun mRNA was performed using SYBR
Green-PCR-Master-Mix (Applied Biosystems). Relative expression
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 DDCT method. Primer
sequences are provided in Supplementary Table 1.
ELISA and western blotting
ELISA and western blot analysis were performed as described
(Leupold et al, 2007; Mudduluru and Allgayer, 2008). In brief, for
ELISA, cells were either treated with DMSO or with Enz for 24h. For
western blot analysis, cells were serum starved for 24h and treated
with DMSO or Enz for another 24h. Cells were stimulated with EGF
(100nM) for 15min. Cells were washed twice with ice-cold PBS and
lysed with lysis buffer (Biosource, Camarillo, CA, USA). Protein
concentration was determined by BCA (Pierce, Rockford, IL, USA).
The u-PAR protein was assayed using the Imubind-u-PAR-ELISA kit
(American Diagnostica, Hauppauge, NY, USA).
Transfection of si-uPAR
si-u-PAR(ID289377; Ambion, Austin, TX, USA) was used to
knockdown the expression of u-PAR. A nonspecific si-RNA
(scrambled) served as a negative control. Sh-RNA vectors of sh-
u-PAR (RHS4430-99290516), and non-silencing control (RHS4346)
were purchased from Open Biosystems (Huntsville, AL, USA).
A549 and H1299 cells were transiently transfected using RNAiFect
or Effectene, respectively (Qiagen). At 24h after transfection, cells
were used for MTT and Matrigel assays as described.
Apoptosis assays
Cells (1 10
6 per ml) were treated with Enz (as the respective IC50
values) and harvested after 48h either with or without transfections.
Apoptosis induction by Enz was measured by the FITC Annexin V
Apoptosis Detection Kit I (BD Pharmingen, San Diego, CA, USA) as
described (Querfeld et al, 2006). According to the manufacturer’s
instructions, cells were incubated with 5ml per test FITC-conjugated
annexin V in the presence of 5ml per test PI, and further screened by
flow cytometry (BD Biosciences, San Diego, CA, USA). Annexin
V-positive PI-positive cells correspond to apoptotic cells and are
represented as a percent of apoptotic cells against DMSO-treated cells.
Electrophoretic mobility shift and ChIP assay
Gel shifts were performed as described (Mudduluru and Allgayer,
2008), using 5mg of nuclear extract of DMSO- or Enz-treated (IC50,
24h) A549 cells. Chromatin immunoprecipitation was performed
according to the manufacturer’s protocol (Upstate, Lake Placid,
NY, USA) as described (Leupold et al, 2007; Mudduluru and
Allgayer, 2008), with 2mg specific (Sp1, Sp3, and p-c-Jun) and
nonspecific IgG overnight, using aliquots of precleared lysates.
DNA was purified and eluted with 100ml elution buffer (Qiagen
reaction purification kit). PCR was performed according to
Leupold et al (2007), for region  190/ 171 (u-PAR-AP1).
Amplification of region  152/ 135 (u-PAR-Sp1/Sp3/AP-2a-like)
was performed by SYBR Green Master Mix, with the specific
primers: For 50-AGGCAATCTGGGGACAGAG-30 and Rev
50-GGACTCCTCCCAGACGTTTT-30.
Chorionallantoic membrane assay
The chorionallantoic membrane (CAM) assay was performed as
described (Leupold et al, 2007), with few modifications. Briefly,
2 10
6 cells were inoculated on the CAM of 10-day-old chicken
embryos. On days 12 and 14, chicken embryos were treated
intravenously with different concentrations of Enz (2 or 4mM)o r
DMSO, respectively. Untreated embryos served as a control. On
day 16, the embryos were killed. Metastasis was determined by
harvesting lungs and liver, and processing the tissue for genomic
human DNA by quantitative alu-PCR.
Statistical analysis
Statistical significance of differences between Enz- vs DMSO-
treated samples were calculated with the Student’s t-test (Pp0.05
was considered as statistically significant, Pp0.1 as a trend).
RESULTS
Enzastaurin inhibits the growth of human NSCLC cells
Six human NSCLC cell lines were tested for their sensitivity to Enz
regarding proliferation (Figure 1A). Large cell-type H460 and
adenocarcinoma LXF289 cells showed the highest sensitivity. A
moderate response was observed in H1395 (adenocarcinoma) and
A427 (squamous carcinoma) cells, whereas A549 (squamous
carcinoma) and H1299 (adenocarcinoma) cells showed compara-
tively more resistance to Enz. Mean IC50 values of the cells are
presented in the box in Figure 1A. Similarly, viable cells were
counted after Enz treatment, confirming the IC50 concentrations
determined by MTT assays (data not shown). Next, to determine if
the calculated IC50 concentrations of Enz were able to induce
apoptosis and inhibit the known target molecules of Enz, apoptotic
assays and western blot analysis were performed. H460, A549, and
H1299 cells were treated for 48h with their respective IC50
concentrations. Enzastaurin (IC50 concentrations) induced apop-
tosis of H460, A549, and H1299 cells compared with the DMSO-
treated samples was shown in Figure 1B. Because EGFR-induced
signalling represents a major pathway driving NSCLC progression,
we in addition sought to investigate the ability of Enz to inhibit
essential target molecules following EGF stimulation. H460, A549,
and H1299 cells were pretreated either with DMSO, or with Enz, for
24h, and stimulated, or unstimulated, with EGF (100nmoll
 1) for
15min before harvesting the cells. As results, we found that Enz
treatment can inhibit the phosphorylation of PKC, AKT, p42/44,
and GSK3b both in the presence and in the absence of EGF
(Figure 1C, Supplementary Figure 1).
Enzastaurin affects cell migration and invasion
To determine whether Enz affects the migration and invasion of
NSCLC cells in vitro, we evaluated the migratory (wound-healing
assay) and invasive (Transwell in vitro invasion assay) capacity of
H460, A549, and H1299 cells, after treatment. Enzastaurin- or Enz/
EGF-treated cells displayed a significantly reduced migration and
invasion as compared to DMSO- and EGF-stimulated control cells;
respectively (Po0.02; Figure 1D), showing that Enz inhibits EGF-
induced cell migration and invasion in addition to spontaneous
invasion in NSCLC. This prompted further experiments to study
changes in gene expression upon Enz treatment, to delineate major
target molecules mediating Enz-inhibited invasion.
Analysis of gene expression changes after Enz treatment
To analyse changes in gene expression after Enz treatment, we
applied Illumina Human Sentrix-8 BeadChip assays. A549 cells
were either treated with DMSO, or with Enz, for 24 or 48h at the
same concentration as used for inhibiting invasion. Total RNA was
isolated, labelled, and hybridised to the arrays. After 24h, 1255
genes (616 up, 639 down), and after 48h, 2711 genes (1477 up, 1234
down) were significantly (X1.5-fold) deregulated after Enz
treatment (Supplementary Tables 2 and 3), respectively. Compar-
ing our microarray results with data present in the literature, we
found that a considerable number of genes that have been
described to be either up- or downregulated specifically in NSCLC
in previous publications were significantly altered upon Enz
treatment (Table 1). These genes include genes regulating cell
proliferation, structure, adhesion, migration, invasion, or angio-
genesis, or are cell-cycle regulators. We found that all of these
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Figure 1 Enzastaurin inhibits NSCLC proliferation, migration, and invasion. (A) Cell proliferation of NSCLC after Enz treatment. Data are expressed as the
percentage of control (treated with DMSO) cells. Points, mean±s.d. of three experiments. Resulting IC50 values for Enz for all NSCLC cell lines investigated are
represented in the box. (B) Apoptosis analysis of H460, A549, H1299 after Enz treatment. After 48h of Enz treatment, cells were screened by flow cytometry
and percent of apoptotic cells was calculated against to DMSO-treated cells. (C) Western blot analysis of cells treated with EGF, Enz, or with the combination
of both agents. Specific antibodies against the indicated molecules were used, together with anti-beta-Actin as a loading control. (C and D)P e r c e n t a g eo f
migrating cells (would-healing assay) and invading cells (Matrigel assay). Cells were treated as described in the Materials and Methods section. DMSO-treated
samples served as a control (100%), and other treated samples were calculated and plotted as a percentage of this value. *Po0.05.
Table 1 Enz inversely regulates relevant genes reported for NSCLC
Gene symbol Accession no.
Fold change
(Enz 24/48h vs DMSO) Reference
Cell cycle, proliferation, migration, and angiogenesis
CCND1 NM_053056  5.1 Borczuk et al, 2003
S100P NM_005980  2.3 Beer et al, 2002
MCM 2 NM_004526  2.1 Wikman et al, 2002
CEACAM1 NM_0010249  4.2 Bhattacharjee et al, 2001
PRSS3 NM_002771  2.4 Diederichs et al, 2004
PLAU NM_002658  2.2 Chen et al,2 0 0 1
PLAUR NM_1005376  1.8 Werle et al, 2004; Hayes et al,2 0 0 6
ERBB3 NM_001982  7.4 Beer et al, 2002
FGFR3 NM_000142  4.7 Hellmann et al, 2001
HIF1a NM_001530  2.4 Hayes et al, 2006
IGFBP3 NM_0010133  13 Beer et al, 2002; Hellmann et al, 2001;
Wikman et al, 2002
GADD45A NM_001924 +9.6 Hellmann et al, 2001
Cell adhesion, cell structure, and signal transduction
KRT7 NM_005556  1.7 Beer et al, 2002
KRT8 NM_002264  2.6 Wikman et al, 2002
KRT18 NM_000224  2.1 Wikman et al, 2002
MUC1 NM_0010180  4.1 Borczuk et al, 2003
VEGFC NM_005429  2.4 Borczuk et al, 2003
FGG NM_000509  3.5 Diederichs et al, 2004
SFTPD NM_003019  2.4 Borczuk et al, 2003
ITGB4BP NM_181466 +2.2 Hellmann et al, 2001
PLEC1 NM_201384 +2.4 Hellmann et al, 2001
Tumor suppressor
FHIT NM_002012 +5.0 Zochbauer-Muller et al,2 0 0 2
RASSF1 NM_007182 +2.0 Zochbauer-Muller et al,2 0 0 2
VHL NM_000551 +1.7 Hayes et al, 2006
Other genes
TOP 2A NM_001067  3.8 Hellmann et al, 2001; Wikman et al, 2002
SLC1A5 NM_005628 +2.1 Beer et al, 2002
ABCC3 NM_020037  5.0 Beer et al, 2002
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sgenes as described in Table 1 were inversely regulated upon Enz
treatment in A549 cells as compared to their gene expression status
reported in previous publications on NSCLC for the untreated
situation. Interestingly, three tumour suppressors (FHIT,
RASSF1, and VHL), which have been reported to be downregulated
in NSCLC (Wikman et al, 2002; Hayes et al, 2006), were
upregulated upon Enz treatment, which was validated by RT–
PCR (Figure 2A–C) at the mRNA level. Also, HIF1a, VEGFC, and
u-PAR (Chen et al, 2001; Werle et al, 2004; Hayes et al, 2006),
genes that are known to be key regulators of various aspects of
carcinogenesis, invasion, and metastasis, were significantly down-
regulated after Enz treatment. The expression of these genes was
validated in NSCLC cell lines through real-time PCR, which
confirmed their cell line-independent regulation upon Enz
treatment (Figure 3A–C). Taken together, Enz negatively regulates
essential genes that are reportedly relevant for NSCLC, induces
the expression of three NSCLC-related tumour-suppressors, and
inhibits three essential genes of invasion and metastasis at the
mRNA level.
Enzastaurin inhibits u-PAR gene expression in NSCLC cells
The u-PAR has been reported to be one of the major metastasis-
related genes being overexpressed in many cancer types, and also
in NSCLC (Beer et al, 2002; Werle et al, 2004). Previous reports
including our own have shown that an overexpression of this
receptor is associated with a high invasive and metastatic capacity
of NSCLC, and also EGF-induced, NSCLC cells, among other
cancer types (Nikolova et al, 2009). Therefore, we decided to
specifically analyse a putative function of the u-PAR in Enz-
regulated invasion, and molecular mediators addressed by Enz to
regulate u-PAR in NSCLC. ELISA showed a significant reduction of
u-PAR protein after Enz treatment in H460 (P¼0.0021), A549
(P¼0.02), and H1299 (P¼0.0022) cells as compared to the DMSO-
treated samples (Figure 4A), in addition to the downregulation of
u-PAR mRNA observed in the same cell lines in the previous
section. It has been well reported that u-PAR gene expression in
malignant cells is largely because of the transcriptional regulation
of the gene (Allgayer et al, 1999; Laufs et al, 2006; Leupold et al,
2007). Specifically, it has been reported that the u-PAR promoter,
to a major part, is being regulated by transcription factors of the
AP-1 and Sp family (Allgayer et al, 1999; Laufs et al, 2006; Leupold
et al, 2007). Correspondingly, we found that Enz treatment in A549
and H1299 cells significantly downregulated the expression of Sp1-,
Sp3-, and c-Jun-transcription factors (Po0.05; Supplementary
Figure 2), which have been reported previously to be major
regulators of u-PAR promoter activity. In luciferase assays of
H460, A549, and H1299 cells transfected with a reporter plasmid
driven by the  398/þ51 upstream region of the u-PAR gene, we
found a significant reduction in u-PAR wild-type promoter activity
after Enz treatment (Po0.008) (Figure 4B). Moreover, site-directed
mutagenesis abolishing the binding of either Sp- or AP-1-family
members to their respective binding sites within the u-PAR
promoter abolished the ability of Enz to induce a further reduction
of promoter activity of the respective construct (Figure 4C). This
was paralleled by a specific reduction of the binding of either Sp1,
Sp3, or AP-1-family members to their specific cis elements within
the u-PAR promoter in EMSA analysis (Supplementary Figure 3b
and c), which could also be observed for the situation of EGF-
induced A549 cells (Supplementary Figure 3a). Finally, to show
that Enz is able to regulate transcription factor binding to the
natural u-PAR promoter, we performed ChIP analysis for the
endogenous u-PAR upstream region. Chromatin immunoprecipi-
tation revealed significantly less binding of especially Sp1, and
phospho-c-Jun, to the endogenous u-PAR promoter after Enz
treatment (Figure 4D, Supplementary Figure 3d). Taken together,
data suggest that Enz inhibits the expression of the u-PAR, at least
to a relevant part by suppressing u-PAR promoter activity, by
downregulation of the binding of especially Sp1, and c-Jun out of
the AP-1 family.
u-PAR knockdown re-sensitises NSCLC cells and induces
apoptosis to Enz
A427, A459, and H1299 are relatively resistant to Enz treatment as
compared to other NSCLC cell lines. This observation supported
the notion that endogenous u-PAR gene expression might be
associated with resistance to Enz. Therefore, we conducted specific
knockdown experiments with an si-RNA/sh-RNA against endo-
genous u-PAR, the efficient knockdown of endogenous u-PAR
being confirmed with u-PAR-ELISA (Supplementary Figure 4a and
b). We observed that A549 and H1299 cells treated with si-u-PAR/
sh-u-PAR were significantly re-sensitised to Enz (A549/
IC50p7.0mM; H1299/IC50p9.0mM) when compared to scrambled
control-transfected cells (A549/IC50¼10mM; H1299/IC50¼12mM)
(Figure 4E). Similarly, viable cells were counted after Enz
treatment either with scrambled/sh-RNA or with si-u-PAR/sh-u-
PAR knockdown, which confirmed the IC50 concentrations
determined by MTT assay (data not shown). Furthermore,
u-PAR knockdown cells significantly induced apoptosis when
compared with control cells after 48h of Enz treatment
(Figure 4F), and also showed a further decrease in u-PAR protein
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Figure 2 Enzastaurin induces the expression of tumour-suppressor
genes. Real-time PCR quantification of (A) VHL,( B) RASSF1, and (C) FHIT
mRNA in H460 and A549 cells after 24–48h of DMSO or Enz (IC50)
treatment. Relative gene expression was normalised against b-Actin
mRNA. *Po0.05.
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slevels after Enz treatment (Supplementary Figure 4a and b). These
data suggest that u-PAR might be one molecular parameter
indicating Enz resistance of NSCLC cells.
Enzastaurin reduces distant metastasis of NSCLC
cells in vivo
Our previous results suggested that Enz reduces migration and
invasion in vitro. To strengthen these observations, we used the
chicken embryo metastasis assay (CAM) (Leupold et al, 2007) to
check the ability of Enz to inhibit the formation of distant
metastasis in vivo. Towards this end, H460, A549, and H1299 cells
were inoculated on the upper CAM of 10-day-old chicken embryos.
On day 12 and 14, the embryos were treated intravenously with 2
or 4mM of Enz, or equal concentrations of DMSO, respectively. On
day 16, the embryos were killed, lungs and livers harvested for
DNA, and the number of cells metastasised into livers and lungs
were measured with a TaqMan-based PCR amplifying human alu-
sequences on the chicken background (Leupold et al, 2007). As a
result, we found that Enz was able to reduce the formation of
distant metastasis significantly in H460 (liver P¼0.001, lungs
P¼0.003), A549 (liver P¼0.037, lungs Pp0.01), and H1299 (liver
P¼0.02, lungs P¼0.05) cells when compared with their respective
DMSO controls (Figure 5A–C). These data suggest that Enz,
besides migration and invasion, inhibits in vivo metastasis of three
NSCLC cell lines.
DISCUSSION
This is the study to show that Enz inhibits migration, invasion, and
in vivo metastasis in NSCLC, and to explore first mechanisms
contributing to Enz-induced inhibition of migration, invasion, and
metastasis-related processes in NSCLC. We show that Enz
transcriptionally inhibits u-PAR gene expression, downregulates
the tumour progression-related molecules HIF1a and VEGFC, and
also upregulates the tumour-suppressor genes VHL, RASSF1, and
FHIT. Furthermore, our findings suggest that an si-u-PAR/
sh-u-PAR knockdown sensitises resistant NSCLC cells to Enz
and induces apoptosis. These findings suggest that Enz treatment
in NSCLC patients might contribute to enhancing their survival by
inhibiting genes of tumour progression and by inducing tumour-
suppressor genes.
Enzastaurin was initially developed as a specific inhibitor of
PKCb, also inhibiting the other PKC isoforms (d, a, e, and g), PI3K/
AKT, GSK3b, and S6K (Faul et al, 2003; Graff et al, 2005; Tekle
et al, 2008; Faoro et al, 2009; Willey et al, 2009; Giovannetti et al,
2010). In agreement with previous studies, our initial observations
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Figure 3 Effect of enzastaurin on the expression of pro-invasive genes. Real-time PCR quantification of (A) HIF1a,( B) VEGFC, and (C) u-PAR mRNA in
H460, A549, and H1299 cells after 24–48h of DMSO or Enz (IC50) treatment. Relative gene expression was normalised against b-Actin mRNA. *Po0.05.
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sin six NSCLC cell lines have shown that Enz inhibits cell growth
and activation of PKC, p-42/44, AKT, and GSK3 b (Faul et al, 2003;
Graff et al, 2005). Furthermore, we in addition show that it inhibits
the EGF-stimulated activation of these kinases. In addition to
initial findings in cultured hepatocellular carcinoma, we now show
that Enz inhibits the in vitro migration and invasion of NSCLC
cells (Guo et al, 2009), and that EGF-induced invasion is countered
by Enz, which is a major pathway in NSCLC progression (Nikolova
et al, 2009). Correspondingly, PKC isoforms have been shown to be
activated in NSCLC cells, and to correlate with tumour progression
in different cancers (Shipp et al, 2002; Clark et al, 2003; Ali et al,
2009; Gokmen-Polar et al, 2001). As further fundamental path-
ways, the MAPK/ERK and PI3K/AKT signalling axis have been
reported to be activated upon PKC activation, which leads to cell
proliferation and anti-apoptosis (Balendran et al, 2000; Goekjian
and Jirousek, 2001). By inhibiting the activation PKC/other
Ser/Thr kinases such as AKT, p-42/44, and GSK3b in NSCLC cells,
in our gene expression array we now found that Enz indeed
significantly downregulates a number of genes that are involved in
different cellular functions such as cell proliferation, anti-
apoptosis, but also cell adhesion, migration, invasion, and
angiogenesis, which are known to be upregulated in the NSCLC
(Bhattacharjee et al, 2001; Chen et al, 2001; Hellmann et al, 2001;
Beer et al, 2002; Wikman et al, 2002; Borczuk et al, 2003;
Diederichs et al, 2004; Werle et al, 2004; Hayes et al, 2006).
Moreover, remarkably, it significantly upregulates the tumour-
suppressor genes (FHIT, RASSF1, and VHL) that are known to be
downregulated in NSCLC (Zochbauer-Muller et al, 2002; Hayes
et al, 2006). It has been reported that the expression of RASSF1 and
FHIT is inhibited in NSCLC tumours, their downregulation
interestingly also having been shown to be associated with
promoter hypermethylation (Zochbauer-Muller et al, 2002). These
tumour-suppressor genes have been implicated as either a pivotal
gatekeeper of cell-cycle progression (Dammann et al, 2000) or a
molecule able to reverse the malignant phenotype and to induce
tumour cell apoptosis (Ji et al, 1999), respectively.
Hypoxia-inducible factor 1a, one of the essential targets of Enz
validated in this study, is getting stabilised in hypoxic conditions,
inactivates tumour-suppressors (p53, PTEN), activates several
oncogenic pathways (Src, HER/2, H-ras) (Zhang et al, 2007), and
transactivates VEGF through hypoxia response elements, this
being central to the initiation of pro-angiogenic signalling and
neovascular formation (Forsythe et al, 1996). Intracellular HIF1a
concentrations are tightly regulated by the von Hippel–Lindau
tumour-suppressor protein, a product of the third tumour-
suppressor gene upregulated by Enz in our study, and a
A549 H1299
80
H460
Scramble
A549
* 60
70
*
sh-RNA
si-u-PAR
sh-u-PAR
30
40
50
120
60
80
100
0
20
40
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
)
10
20 **
02 . 557 . 5 10 15
Enzastaurin (M)
n
g
 
u
-
P
A
R
/
m
g
 
t
o
t
a
l
 
p
r
o
t
e
i
n
12
10
6
8
2
4
0
DMSO Enz
0
DMSO Enz
30
40
20
10
0
DMSO Enz
H1299
Scramble
sh-RNA
A549 H1299 H460 si-u-PAR
sh-u-PAR
100
120
40
60
80
0
20
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
)
**
**
**
Enzastaurin (M)
A549 DMSO
Enz *
P
e
r
c
e
n
t
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
o
f
 
u
-
P
A
R
 
(
–
3
9
8
 
t
o
 
+
5
1
) 120
80
100
40
60
20
0
DMSO Enz pGL3
u-PAR
120
80
100
40
60
20
0
DMSO Enz pGL3
u-PAR
120
80
100
60
20
40
0
DMSO Enz pGL3
u-PAR
150
200
250
50
100
0
Scramble si-u-PAR
%
 
A
p
o
p
t
o
t
i
c
 
c
e
l
l
s
DMSO
DMSO
Enz
H1299 DMSO
*
Enz 
Enz
4.0
3.0
3.5
1.5
2.0
2.5
0.0
0.5
1.0
C
h
r
o
m
a
t
i
n
 
(
n
g
)
80
100
120
40
60
0
20
Sp1
IgG
p-c-Jun
Sp3
300
150
200
250
0
50
100
WT
Sp1 AP-1
pGL3
P
e
r
c
e
n
t
 
I
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
o
f
 
u
-
P
A
R
 
(
–
3
9
8
 
t
o
 
+
5
1
)
Mutant
%
 
A
p
o
p
t
o
t
i
c
 
c
e
l
l
s
0369 1 2 15
Scramble si-u-PAR
Figure 4 Enzastaurin inhibits u-PAR promoter activity and u-PAR protein expression. (A) Total amounts of u-PAR protein as evaluated by ELISA as
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2005). It is an interesting observation of this study that VHL is
getting upregulated, and its targeted molecule HIF1a, in addition
to VEGF that is transactivated by HIF1a, is getting downregulated
upon Enz treatment. Correspondingly, previous reports have
suggested these genes to be inversely regulated in NSCLC
(Forsythe et al, 1996; Wang et al, 2009). In addition, u-PA and
u-PAR, which are upregulated in NSCLC (Werle et al, 2004;
Beyer et al, 2006), are getting downregulated upon Enz treatment
in our study. Interestingly, all three of these tumour progression-
related genes, u-PAR, HIF1a, and VEGFC, are either activated
by the downstream axis of, or transcriptionally regulated at
least in part, by the MAPK/ERK and/or PI3K/AKT pathways
(Jo et al, 2003; Tsai et al, 2003; Phillips et al, 2005; Skurk et al,
2005), which are inhibited by Enz treatment (Faul et al, 2003; Graff
et al, 2005).
The u-PAR is an essential molecule in the context of proteolysis,
migration, invasion, and metastasis (Jo et al, 2003; Dass et al,
2008), and its function and transcriptional regulation are well
studied (Laufs et al, 2006). Interestingly, in our study, Enz
inhibited u-PAR promoter activity by inhibiting the gene
expression and binding of Sp1, Sp3, and c-Jun(AP-1) to the
u-PAR-promoter in vitro and in vivo (ChIP). In the context of
suppressing u-PAR gene expression through Enz, it was an
interesting initial observation in our study that the knockdown
of u-PAR might be able to resensitise relatively resistant NSCLC
cells and induces apoptosis after Enz treatment (Querfeld et al,
2006; Lee et al, 2008; Morgillo et al, 2008). This finding emphasises
the general importance of defining critical molecular markers that
are associated with a potential resistance towards novel targeted
therapy compounds, because otherwise it might lead to the
treatment of patients that, by their molecular condition, are unable
to respond to the novel drug. In fact, this might be one of the
explanations as to why initial clinical trials with Enz that were not
associated with parallel translational molecular studies at the
resected tumour tissue of treated patients, led to initial contra-
dictory results (Casey et al, 2009; Richards et al, 2009; Kreisl et al,
2010; Wick et al, 2010). However, with our results we might give an
additional encouragement for the initiation of more tailored-
therapy clinical studies, in which putatively essential molecular
markers associated with response or resistance are being measured
before the decision for a certain combination of therapies in the
individual patient.
In our paper, we show that Enz inhibits in vivo distant
metastasis to liver and lungs in the CAM assay. Apart from its
pro-apoptotic, growth inhibitory, and anti-angiogenic properties
(Keyes et al, 2002; Graff et al, 2005; Querfeld et al, 2006; Willey
et al, 2009), this could be, at least in part, due to downregulating
tumour progression and invasion-related genes (u-PAR, HIF1a,
and VEGFC) and upregulating NSCLC tumour-related suppressor
genes (FHIT, RASSF1, and VHL) by Enz. We consider it unlikely
that a main mechanism of metastasis inhibition by Enz can be
explained by anti-angiogenesis, because we observed that DMSO-
or Enz-dipped plugs did not show any significant difference in
their effect on the formation of embryonic vasculature of the upper
CAM (data not shown). However, certainly, an anti-angiogenic
component of Enz in the context of anti-metastatic action in our
model cannot be ruled out completely.
Taken together, this is the first comprehensive analysis to
investigate differentially regulated genes in NSCLC cells upon Enz
treatment, and to implicate novel Enz targets in the context of
migration, invasion, and distant metastasis in NSCLC. Our results
suggest that Enz has a major role in downregulating the u-PAR
through Sp1/Sp3 and c-Jun(AP-1), besides HIF1a and VEGFC that
are implicated in tumour growth and metastasis, in parallel to
upregulating tumour-suppressors relevant for NSCLC. Further-
more, the knockdown of u-PAR re-sensitises NSCLC cells to Enz
treatment. These findings give important information for ongoing
clinical trials with Enz in NSCLC patients, and further studies
investigating resected tumour tissue or blood samples of Enz
treated patients for, for example, u-PAR or serum-soluble u-PAR
(Henic et al, 2008), as a potentially clinically relevant marker of
therapy resistance are clearly encouraged.
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Figure 5 Enzastaurin inhibits NSCLC metastasis in vivo.( A–C) Number
of metastasising cells in the livers and lungs of chicken embryos treated
intravenously with different concentrations of Enz (2 or 4mM) or DMSO,
respectively. Human Alu sequences were amplified and quantified by
real-time PCR. **Po0.001; *Pp0.05.
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